As biologic therapies continue to rise for treating cancer, autoimmune, and neurological diseases, drug containment and delivery solutions are evolving to meet these new therapeutic demands.
As the biologics market continues to expand, fuelled by breakthroughs such as cell and gene therapies, drug developers face increasing demand for safe, patient-friendly delivery and administration solutions.
The global large-volume injectors market is expected to witness substantial growth over the next decade, driven by factors such as the rising prevalence of chronic diseases, a shift towards homecare, and technological advancements in injector devices.
Christian Mias, born in Iserlohn in 1974, will succeed Andreas Reisse starting May 1st. As an industrial engineer with a doctoral degree, he looks back on more than 20 years of management experience, including over 18 years within the SCHOTT group.
LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company today announced the successful closing of its acquisition of Renaissance
Gerresheimer, a global systems and solutions provider specialising in pharmaceutical packaging and drug delivery devices, will present its extensive portfolio of high-value solutions for innovative therapies at this year’s CPHI Trade Fair in Frankfurt, Germany, from October 28th to 30th, 2025, in Hall 8 at Booth 8.OG8.
LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality and cost-competitive large-scale manufacturing capacities.
LTS LOHMANN Therapie-Systeme (LTS), a leading pharmaceutical technology company, is proud to announces its selection as a Concept Stage winner for two projects in the #PatchForwardPrize, a $50m challenge by the Biomedical Advanced Research and Development Authority (BARDA) to advance microneedle patch-based RNA vaccine technologies.
Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, achieved solid results and continued to grow profitably in financial year 2024. Revenues reached €2,035.9m (2023: €1,990.5m), while adjusted EBITDA amounted to €419.4m (2023: €404.5m). Organic sales grew by +2.9% and adjusted EBITDA by +4.1%. The adjusted EBITDA margin improved to 20.6% (2023: 20.3%).
Gerresheimer, an innovative systems and solutions provider and global partner to the pharma, biotech and cosmetics industries, is presenting its comprehensive portfolio of containment solutions, drug delivery systems and digital solutions for the first time together with Bormioli Pharma at this year's Pharmapack. The focus of the trade show appearance in Paris on 22 and 23 January 2025 will be on the further expanded portfolio of containment solutions with numerous closure options and accessories following the acquisition of Bormioli Pharma.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.